Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.

Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.

Item
http://www.wikidata.org/entity/Q37625349
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer.A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory.Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice.Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies.Emerging roles of regulatory T cells in tumour progression and metastasis.Luciferase Expression Allows Bioluminescence Imaging But Imposes Limitations on the Orthotopic Mouse (4T1) Model of Breast Cancer.Biodegradable polymeric micelle-encapsulated doxorubicin suppresses tumor metastasis by killing circulating tumor cells.
P2860

Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.

Item
http://www.wikidata.org/entity/Q37625349
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.
@en
Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.
@nl
type
label
Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.
@en
Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.
@nl
prefLabel
Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.
@en
Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P932